Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.635
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Active Eosinophilic Esophagitis: Analysis of the Steroid-Refractory Subgroup From the HEROES Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Markers of Esophageal Epithelial-Mesenchymal Transition Are Significantly Reduced in Active Eosinophilic Esophagitis Following 16 Weeks of Treatment With RPC4046, an Anti-Interleukin-13 Monoclonal Antibody

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics
Pharmacology
2016English

Efficacy of Lanadelumab in Hereditary Angioedema Patients Switching From C1 Inhibitor Long-Term Prophylaxis: Interim Results From the HELP Open-Label Extension Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study

2018English

Long-Term Metformin Treatment in Adolescents With Obesity and Insulin Resistance, Results of an Open Label Extension Study

Nutrition and Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

Journal of the American Academy of Dermatology
Dermatology
2016English

A 52-Week, Open-Label Study Evaluating the Safety and Efficacy of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, for Rheumatoid Arthritis

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy